MIC-1、CYFRA21-1、TMB水平与晚期非小细胞肺癌靶向治疗疗效的相关性

doi:10.3969/j.issn.1671-7171.2022.09.008

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1266 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the correlation of macrophage inhibitory factor 1 (MIC-1),cytokeratin19 soluble fragment (CYFRA21-1),tumor mutational burden (TMB) and related clinical characteristics with the efficacy of targeted therapy for advanced non-small cell lung cancer (NSCLC).【Methods】The clinical data of 118 patients with advanced NSCLC admitted to our hospital were collected and divided into the chemotherapy effective group (n=55) and the chemotherapy ineffective group (n=63) according to the short-term efficacy.The differences of general data and laboratory indicators (MIC-1,CYFRA21-1,TMB) between the two groups were compared.The value of MIC-1 and CYFRA21-1 in predicting the efficacy of advanced NSCLC was analyzed by ROC.The differences between the two groups were included in the multivariate Logistic regression analysis to identify the risk factors affecting the efficacy of advanced NSCLC.【Results】After treatment,10 patients had complete remission,45 patients had partial remission,41 patients had stable disease,and 22 patients had progressive disease.The total effective rate was 46.61% (55/118).There were no significant differences in gender,body mass index (BMI),tumor diameter and drinking history between the two groups (P>0.05).The proportion of patients with ≥60 years old,squamous cell carcinoma,poorly differentiated,TNM stage Ⅳ,smoking history,moderate or low TMB level in the chemotherapy ineffective group was significantly higher than that in the chemotherapy effective group (P<0.05).ROC analysis confirmed that MIC-1 and CYFRA21-1 could be used to predict the efficacy of advanced NSCLC,and the areas under the curve were 0.798 and 0.801,respectively (both P<0.05).Multivariate Logistic regression analysis confirmed that ≥60 years old,squamous cell carcinoma,low differentiation,TNM stage Ⅳ,smoking history,moderate to low TMB level,MIC-1≥1030.030 pg/mL,CYFRA21-1≥9.095 μg/mL were risk factors affecting the efficacy of targeted therapy for advanced NSCLC (P<0.05).【Conclusion】The level of TMB in tumor tissue and the efficacy of targeted therapy for advanced NSCLC are affected by many factors,such as age,pathological type,degree of differentiation,TMB level in tumor tissue,MIC-1,CYFRA21-1,etc.Clinicians should pay close attention to them when treating advanced NSCLC.

Key words： Carcinoma,Non-Small-Cell Lung Growth Differentiation Factor 15 Keratins Treatment Outcome

Received: 28 March 2022

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Guo-xia
	LIU Xiang-ling

Cite this article:

LI Guo-xia,LIU Xiang-ling. Correlation of MIC-1,CYFRA21-1 and TMB Levels with Efficacy of Targeted Therapy for Advanced Non-small Cell Lung Cancer[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(9): 1307-1310.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.09.008 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I9/1307

[1] SZEJNIUK W M,ROBLES A,MC C T,et al.Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer,current state-of-art[J].Pharmacogenomics J,2019,19(1):5-14.
[2] MENDER I,RANGER R L,LUITEL K,et al.Telomerase-mediated strategy for overcoming non-small cell lung cancer targeted therapy and chemotherapy resistance[J].Neoplasia,2018,20(8):826-837.
[3] 童琳,周建,白春学,等.晚期非小细胞肺癌患者肿瘤突变负荷与靶向治疗疗效相关性[J].中国临床医学,2019,26(4):538-542.
[4] EISENHAUER E,THERASSE P,BOGAERTS J,et al.32 INVITED New response evaluation criteria in solid tumors:revised RECIST guideline version 1.1[J].EJC Suppl,2019,25(3):1063-1069.
[5] OFFIN M,RIZVI H,TENET M,et al.Tumor mutation burden and efficacy of egfr-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers[J].Clin Cancer Res,2019,25(3):1063-1069.
[6] 李春燕,李索妮,翟阳.吉非替尼联合吉西他滨和顺铂化疗方案治疗老年晚期EGFR突变型非小细胞肺癌的疗效观察[J].中国肿瘤临床与康复,2019,26(8):925-928.
[7] 谭钦全,江冠铭,刘克军,等.血小板/淋巴细胞比值对表皮生长因子受体突变型晚期非小细胞肺癌靶向治疗效果及预后影响的观察性研究[J].癌症进展,2020,18(7):690-693.
[8] 张宁,王丽华,王洪海.非小细胞肺癌靶向治疗后患者血清MIC-1水平与治疗效果的相关性[J].实用癌症杂志,2021,36(6):888-890.
[9] 刘亚杰,马晓波.肿瘤标志物GSTP1,CYFRA21-1及SCC-Ag对非小细胞肺癌的预后评估价值[J].中国现代医学杂志,2020,30(14):42-46.
[10] 殷悦,张羽白,邢丽娜.肿瘤突变负荷对非小细胞肺癌免疫治疗疗效的预测价值[J].中华老年多器官疾病杂志,2018,17(9):717-720.
[11] 赵呈龙,李力,王玉波,等.PD-L1表达联合TMB预测免疫检查点抑制剂治疗NSCLC疗效的研究[J].重庆医学,2021,50(10):1621-1627.
[12] ROBERT C,LONG G V,BRADY B,et al.Nivolumab in previously untreated melanoma without BRAF mutation[J].N Engl J Med,2015,372(4):320-330.